Artesunate--amodiaquine combination therapy for falciparum malaria in young Gabonese children - PubMed (original) (raw)

Clinical Trial

Artesunate--amodiaquine combination therapy for falciparum malaria in young Gabonese children

Sunny Oyakhirome et al. Malar J. 2007.

Abstract

Background: Artesunate-amodiaquine combination for the treatment of childhood malaria is one of the artemisinin combination therapies (ACTs) recommended by National authorities in many African countries today. Effectiveness data on this combination in young children is scarce.

Methods: The effectiveness of three daily doses of artesunate plus amodiaquine combination given unsupervised (n = 32), compared with the efficacy when given under full supervision (n = 29) to children with falciparum malaria were assessed in an unrandomized study.

Results: 61 patients analysed revealed a PCR-corrected day-28 cure rate of 86 % (25 of 29 patients; CI 69-95 %) in the supervised group and 63 % (20 of 32 patients; CI 45-77 %) in the unsupervised group. The difference in outcome between both groups was statistically significant (p = 0.04). No severe adverse events were reported.

Conclusion: The effectiveness of this short course regimen in young children with falciparum malaria could be augmented by increased adherence and improved formulation.

PubMed Disclaimer

Figures

Figure 1

Trial profile.

Similar articles

• Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial.
  Adjuik M, Agnamey P, Babiker A, Borrmann S, Brasseur P, Cisse M, Cobelens F, Diallo S, Faucher JF, Garner P, Gikunda S, Kremsner PG, Krishna S, Lell B, Loolpapit M, Matsiegui PB, Missinou MA, Mwanza J, Ntoumi F, Olliaro P, Osimbo P, Rezbach P, Some E, Taylor WR. Adjuik M, et al. Lancet. 2002 Apr 20;359(9315):1365-72. doi: 10.1016/s0140-6736(02)08348-4. Lancet. 2002. PMID: 11978332 Clinical Trial.
• Randomized, multicentre assessment of the efficacy and safety of ASAQ--a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria.
  Ndiaye JL, Randrianarivelojosia M, Sagara I, Brasseur P, Ndiaye I, Faye B, Randrianasolo L, Ratsimbasoa A, Forlemu D, Moor VA, Traore A, Dicko Y, Dara N, Lameyre V, Diallo M, Djimde A, Same-Ekobo A, Gaye O. Ndiaye JL, et al. Malar J. 2009 Jun 8;8:125. doi: 10.1186/1475-2875-8-125. Malar J. 2009. PMID: 19505304 Free PMC article. Clinical Trial.
• Artemisinin-based combination therapy for uncomplicated Plasmodium falciparum malaria in Colombia.
  Osorio L, Gonzalez I, Olliaro P, Taylor WR. Osorio L, et al. Malar J. 2007 Feb 28;6:25. doi: 10.1186/1475-2875-6-25. Malar J. 2007. PMID: 17328806 Free PMC article. Clinical Trial.
• [Combined antimalarial therapy using artemisinin].
  Majori G. Majori G. Parassitologia. 2004 Jun;46(1-2):85-7. Parassitologia. 2004. PMID: 15305693 Review. Italian.
• Artesunate-amodiaquine for the treatment of uncomplicated malaria.
  Sirima SB, Gansané A. Sirima SB, et al. Expert Opin Investig Drugs. 2007 Jul;16(7):1079-85. doi: 10.1517/13543784.16.7.1079. Expert Opin Investig Drugs. 2007. PMID: 17594191 Review.

Cited by

• Slow clearance of histidine-rich protein-2 in Gabonese with uncomplicated malaria.
  Lamsfus Calle C, Schaumburg F, Rieck T, Nkoma Mouima AM, Martinez de Salazar P, Breil S, Behringer J, Kremsner PG, Mordmüller B, Fendel R. Lamsfus Calle C, et al. Microbiol Spectr. 2024 Oct 3;12(10):e0099424. doi: 10.1128/spectrum.00994-24. Epub 2024 Aug 28. Microbiol Spectr. 2024. PMID: 39194289 Free PMC article.
• Funding patterns for biomedical research and infectious diseases burden in Gabon.
  Adegnika OS, Honkpehedji YJ, Mougeni Lotola F, Agnandji ST, Adegnika AA, Lell B, Sicuri E. Adegnika OS, et al. BMC Public Health. 2021 Nov 24;21(1):2155. doi: 10.1186/s12889-021-12201-w. BMC Public Health. 2021. PMID: 34819025 Free PMC article.
• Differential Prevalences of Pfmdr1 Polymorphisms in Symptomatic and Asymptomatic Plasmodium falciparum Infections in Lastoursville: A Rural Area in East-Central Gabon.
  Ontoua SS, Kouna LC, Oyegue-Liabagui SL, Voumbo-Matoumona DF, Moukodoum DN, Imboumy-Limoukou RK, Lekana-Douki JB. Ontoua SS, et al. Infect Drug Resist. 2021 Jul 24;14:2873-2882. doi: 10.2147/IDR.S304361. eCollection 2021. Infect Drug Resist. 2021. PMID: 34335033 Free PMC article.
• Monitoring of efficacy, tolerability and safety of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Lambaréné, Gabon: an open-label clinical trial.
  Adegbite BR, Edoa JR, Honkpehedji YJ, Zinsou FJ, Dejon-Agobe JC, Mbong-Ngwese M, Lotola-Mougueni F, Koehne E, Lalremruata A, Kreidenweiss A, Nguyen TT, Kun J, Agnandji ST, Lell B, Safiou AR, Obone Atome FA, Mombo-Ngoma G, Ramharter M, Velavan TP, Mordmüller B, Kremsner PG, Adegnika AA. Adegbite BR, et al. Malar J. 2019 Dec 16;18(1):424. doi: 10.1186/s12936-019-3015-4. Malar J. 2019. PMID: 31842893 Free PMC article. Clinical Trial.
• Hematological and biochemical effects of sub-chronic artesunate exposure in rats.
  Bigoniya P, Sahu T, Tiwari V. Bigoniya P, et al. Toxicol Rep. 2015 Jan 25;2:280-288. doi: 10.1016/j.toxrep.2015.01.007. eCollection 2015. Toxicol Rep. 2015. PMID: 28962361 Free PMC article.

References

1. 1. Snow RN, Craig M, Deichmann U, Marsh K. Estimating mortality, morbidity and disability due to malaria among Africa's non-pregnant population. Bull World Health Organ. 1999;77:624–640. - PMC - PubMed
2. 1. Trape JF, Pison G, Preziosi MP, Enel C, Desgrees du Lou A, Delaunay V, Samb B, Lagarde E, Molez JF, Simondon F. Impact of chloroquine resistance on malaria mortality. C R Acad Sci III. 1998;321:689–697. - PubMed
3. 1. Breman JG, Egan A, Keusch GT. The intolerable burden of malaria: a new look at the numbers. Am J Trop Med Hyg. 2001;64:iv–vii. - PubMed
4. 1. White NJ. Antimalarial drug resistance: the pace quickens. J Antimicrob Chemother. 1992;30:571–585. doi: 10.1093/jac/30.5.571. - DOI - PubMed
5. 1. Hien TT, White NJ. Qinghaosu. Lancet. 1993;341:603–608. doi: 10.1016/0140-6736(93)90362-K. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • BioMed Central
  • Europe PubMed Central
  • PubMed Central